Structured Representation of the Pharmacodynamics Section of the Summary of Product Characteristics for Antibiotics: Application for Automated Extraction and Visualization of Their Antimicrobial Activity Spectra

Duclos, Catherine; Cartolano, Gian Luigi; Ghez, Michael; Venot, Alain

doi:10.1197/jamia.m1425

Cited by 6 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some were proposed for monitoring changes in a particular phenomenon, such as the frequency of nosocomial infections [25] or respiratory monitoring results [26,27]. Others aim to visually present elements of the current state of a patient, such as mammography results [28], the results of a clinical trial [29], or for facilitating the comparison of antibiotic spectra [30]. …”

Section: Introductionmentioning

confidence: 99%

An iconic language for the graphical representation of medical concepts

Lamy

Duclos

Bar-Hen

et al. 2008

BMC Med Inform Decis Mak

View full text Add to dashboard Cite

Background: Many medication errors are encountered in drug prescriptions, which would not occur if practitioners could remember the drug properties. They can refer to drug monographs to find these properties, however drug monographs are long and tedious to read during consultation. We propose a two-step approach for facilitating access to drug monographs. The first step, presented here, is the design of a graphical language, called VCM.

show abstract

Section: Introductionmentioning

confidence: 99%

An iconic language for the graphical representation of medical concepts

Lamy

Duclos

Bar-Hen

et al. 2008

BMC Med Inform Decis Mak

View full text Add to dashboard Cite

show abstract

“…Our model is based on the knowledge of two experts in the representation of drug information [8-14], as well as on the analysis of the information for 60 recently approved new drugs, covering a broad spectrum in terms of novelty and therapeutic use.…”

Section: Discussionmentioning

confidence: 99%

“…We constructed a preliminary conceptual model of pharmaceutical innovations based on the knowledge of two of the authors of this paper, CD and AV, who are experienced in the field of drug-information modeling [8-14]. We then refined this model, using a random sample of 40 new manufactured products that had recently been approved by the national drug authorities in France.…”

Section: Methodsmentioning

confidence: 99%

Designing concept maps for a precise and objective description of pharmaceutical innovations

Iordatii

Venot

Duclos

2013

BMC Med Inform Decis Mak

View full text Add to dashboard Cite

BackgroundWhen a new drug is launched onto the market, information about the new manufactured product is contained in its monograph and evaluation report published by national drug agencies. Health professionals need to be able to determine rapidly and easily whether the new manufactured product is potentially useful for their practice. There is therefore a need to identify the best way to group together and visualize the main items of information describing the nature and potential impact of the new drug. The objective of this study was to identify these items of information and to bring them together in a model that could serve as the standard for presenting the main features of new manufactured product.MethodsWe developed a preliminary conceptual model of pharmaceutical innovations, based on the knowledge of the authors. We then refined this model, using a random sample of 40 new manufactured drugs recently approved by the national drug regulatory authorities in France and covering a broad spectrum of innovations and therapeutic areas. Finally, we used another sample of 20 new manufactured drugs to determine whether the model was sufficiently comprehensive.ResultsThe results of our modeling led to three sub models described as conceptual maps representingi) the medical context for use of the new drug (indications, type of effect, therapeutical arsenal for the same indications), ii) the nature of the novelty of the new drug (new molecule, new mechanism of action, new combination, new dosage, etc.), and iii) the impact of the drug in terms of efficacy, safety and ease of use, compared with other drugs with the same indications.ConclusionsOur model can help to standardize information about new drugs released onto the market. It is potentially useful to the pharmaceutical industry, medical journals, editors of drug databases and medical software, and national or international drug regulation agencies, as a means of describing the main properties of new pharmaceutical products. It could also used as a guide for the writing of comprehensive and objective texts summarizing the nature and interest of new manufactured product.

show abstract

Conception d’une interface pour favoriser la prise en compte des recommandations lors de la décision d’une antibiothérapie probabiliste

Tsopra¹,

Venot²,

Duclos³

2011

Informatique Et Santé

View full text Add to dashboard Cite

Structured Representation of the Pharmacodynamics Section of the Summary of Product Characteristics for Antibiotics: Application for Automated Extraction and Visualization of Their Antimicrobial Activity Spectra

Abstract: This tool can provide an overview of the prevalence of resistance as expressed in SPC in primary care settings. Its potential impact should be evaluated.

Cited by 6 publications

References 31 publications

An iconic language for the graphical representation of medical concepts

An iconic language for the graphical representation of medical concepts

Designing concept maps for a precise and objective description of pharmaceutical innovations

Conception d’une interface pour favoriser la prise en compte des recommandations lors de la décision d’une antibiothérapie probabiliste

Contact Info

Product

Resources

About